Last data update: 29 July 2021 10:25 CEST
Plasmid name: pAS2-mRIP1 (LMBP 6680)
|New search||Print data sheet|
|Price category:||Cat. 1 (cf. price list)|
|Status:||GeneCorner core plasmid|
(View with Genome Compiler)
Mouse receptor TNFRSF-interacting serine-threonine kinase 1 cDNA (Ripk1, Rip1, Rinp, GeneID 19766)|
Saccharomyces cerevisiae GAL4 DNA-binding domain (GALbd)
Influenza HA epitope encoding the haemagglutinin tagging peptide; N-terminal
|Promoter:||Saccharomyces cerevisiae alcohol dehydrogenase promoter (ADH1)
Escherichia coli lac operon promoter
|Terminator:||Saccharomyces cerevisiae alcohol dehydrogenase terminator (ADH1)
Saccharomyces cerevisiae iso-1-cytochrome C terminator (CYC1)
Saccharomyces cerevisiae 2 micron plasmid (2μ) FLP terminator
|Selection marker:||Ampicillin (amp)
|Replicon:||Escherichia coli plasmid pMB1 origin
Phage f1 origin
Saccharomyces cerevisiae 2 micron plasmid origin (2μ); incl. region conferring stability (STB)
|Host range:||Escherichia coli
Saccharomyces cerevisiae; trp1(-)
|Parental clone:||pAS2; pGEM-RIP|
|Further information:||The plasmid was constructed by PCR amplifying the mRIP1 coding sequence from pGEM-RIP and ligating it as an NheI/BamHI fragment into the NheI/BamHI opened pAS2 vector. As a result, the mouse RIP1 coding sequence was fused in phase to the N-terminal GAL4 DNA-binding domain and HA epitope.
The S. cerevisiae GALbd is composed of the first 147 codons from GAL4, containing the nuclear localization signal.
The GALbd-HA-mRIP1 fusion protein can be used as a bait protein in two-hybrid screening.
pAS2-mRIP1 carries the S. cerevisiae tryptophan 1 coding sequence (TRP1) and the CYH2 sequence encoding ribosomal protein L29 for dominant cycloheximide sensitivity which facilitates the elimination of false positives.
The nucleotide sequence of this plasmid corresponds with the EMBL Nucleotide Sequence Database accession number LT726839.1.
The nucleotide sequence of the pAS2 vector corresponds with the EMBL Nucleotide Sequence Database accession number U30496.1, except for the following adaptations: 1) the 'N' nucleotide was removed, restoring the coding sequence of cycloheximide; 2) the sequence GATTTC between GALbd and the HA epitope was replaced by GAATTC, an EcoRI site that has been experimentally confirmed in pAS2; 3) the sequence TTCGAA (Csp45I site) in the ADH1 promoter was replaced by TCGAAG, eliminating the Csp45I site that could not be experimentally confirmed in pAS2.
The nucleotide sequence of the mouse RIP1 cDNA corresponds with the EMBL Nucleotide Sequence Database accession number BC058162.1.
Other name of the plasmid is pAS2-mRIP.
|EMBL Accession number:||BC058162.1, view at EMBL, GenBank, DDBJ
U30496.1, view at EMBL, GenBank, DDBJ
LT726839.1, view at EMBL, GenBank, DDBJ
|Latest sequence update:||25/02/2009|
Primers used for isolating the mouse RIP1 coding sequence: Forward: 5' GGTACGCTAGC.ATG.CAA.CCA.GAC.ATG.TCC 3' NheI *** Reverse: 5' CGCGGATCC.TTA.GCT.CTG.GCT.GGC.ACG 3' BamHI +++ ***: start codon. +++: termination codon.
|Authenticity test:||Restriction enzyme pattern analysed at GeneCorner: BamHI/NheI, BglII, EcoRI and XmnI.|
|History of deposit:||This plasmid was deposited by Prof. Dr R. Beyaert(1) (2).
(1) Department for Molecular Biomedical Research, VIB, Ghent, Belgium
(2) Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
|Restricted distribution:||- BCCM MTA|
|Distributed as:||H/P active culture or plasmid DNA|
|Host for distribution:||Escherichia coli K12 MC1061|
|Host reference:||Casadaban et al., J. Mol. Biol. 138 (1980), 179-207 [PMID: 6997493]
|Related host reference:||Brigé et al., Biochem. J. 394 (2006), 335-344 [PMID: 16293111]
|Cultivation medium:||LB-Lennox + ampicillin (100 μg/ml)|
|Other culture collection numbers:||-|
Refer in your Materials and Methods:
|pAS2-mRIP1 (LMBP 6680) is available at BCCM/GeneCorner. This plasmid was deposited by Prof. Dr R. Beyaert .|
Note: Up-to-date, validated data are enclosed with the biological material. Nevertheless, these data are a snapshot at a given moment; further updates are always possible.